Safety, Pharmacokinetics,and Antiviral Activity of RV299 Against Respiratory Syncytical Virus (RSV)

NCT06067191 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

82

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Syncytial Virus (RSV)

Interventions

DRUG: RV299
DRUG: Placebo

Sponsor

Pfizer